Payment overview · 2025
General Payments
$80,846.86
459 reported records · 36 companies
Healthcare provider profile · identity verified
April O. Swoner, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HERMITAGE, TN · NPI 1972007201
Verified facts
What the public records show
CMS Open Payments records show April O. Swoner, NP received $80,846.86 in general payments during 2025 across 459 reported records.
ACADIA Pharmaceuticals Inc accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Briviact, Nuplazid, Nurtec Odt, Privigen, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGENTYS as an associated drug or biological on 728 records involving 311 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ongentys by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rytary by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Privigen by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gocovri by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Nurtec Odt by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $25,157.62 | 31.1% | 37 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15,178.89 | 18.8% | 73 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13,669.20 | 16.9% | 42 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $11,967.51 | 14.8% | 27 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $8,982.01 | 11.1% | 25 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $970.28 | 1.2% | 24 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $424.65 | 0.5% | 19 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $403.22 | 0.5% | 29 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $398.60 | 0.5% | 11 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$364.14 | 0.5% | 16 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $344.23 | 0.4% | 8 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $340.21 | 0.4% | 15 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $316.74 | 0.4% | 14 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $234.61 | 0.3% | 20 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $229.57 | 0.3% | 9 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $218.98 | 0.3% | 11 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $193.11 | 0.2% | 7 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $191.13 | 0.2% | 7 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $150.23 | 0.2% | 10 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $141.37 | 0.2% | 6 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $139.21 | 0.2% | 7 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $92.03 | 0.1% | 4 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $86.07 | 0.1% | 5 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $84.33 | 0.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.27 | 0.1% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $67.21 | 0.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $66.32 | 0.1% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.75 | 0.1% | 4 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $59.11 | 0.1% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $51.09 | 0.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.81 | 0.1% | 3 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $37.89 | 0.1% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$37.25 | 0.1% | 2 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $24.03 | 0.0% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $23.66 | 0.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.53 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $40,303.51 | 28 |
| Honoraria | $19,907.25 | 10 |
| Food and Beverage | $9,936.99 | 380 |
| Travel and Lodging | $9,849.11 | 39 |
| Consulting Fee | $850.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $25,157.62 | 37 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $13,669.20 | 42 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $11,967.51 | 27 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $8,437.56 | 23 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $7,548.87 | 41 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $5,740.22 | 25 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $4,891.17 | 33 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $812.75 | 12 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $424.65 | 19 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $398.60 | 11 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $363.99 | 8 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $344.23 | 8 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $316.74 | 14 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $293.82 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $234.61 | 20 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $193.11 | 7 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $191.13 | 7 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $177.66 | 6 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $163.38 | 8 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $162.38 | 7 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $152.11 | 8 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $150.23 | 10 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $139.21 | 7 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $118.76 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $118.23 | 6 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $115.39 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $92.03 | 4 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $86.07 | 5 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $84.33 | 4 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $81.97 | 3 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $75.27 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $75.27 | 4 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $68.12 | 2 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $67.21 | 3 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $65.75 | 4 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $59.11 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $51.09 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $48.38 | 3 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $46.81 | 3 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $37.89 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $37.25 | 2 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $23.66 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| Privigen Normalized: privigen |
Biological | CSL Behring | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $4.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 48 | exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 45 | exact normalized | Medicare Part D |
| Privigen privigen |
2025 | Privigen | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 91 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
48 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
91 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
79 | 20 |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | ONGENTYS open payments reported associated product |
CMS Open Payments — General Payments 728 supporting records · 311 recipient NPIs · example record 1220525547 |
Ongentys · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
45 | 15 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 188 | 60 |
| Gabapentin | Gabapentin | 166 | 57 |
| Levetiracetam | Levetiracetam | 145 | 34 |
| Memantine Hcl | Memantine Hcl | 133 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 45 |
| Primidone | Primidone | 121 | 28 |
| Topiramate | Topiramate | 121 | 30 |
| Lamotrigine | Lamotrigine | 103 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 96 | 30 |
| Qulipta | Atogepant | 91 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 88 | 20 |
| Ubrelvy | Ubrogepant | 79 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 75 | 17 |
| Oxcarbazepine | Oxcarbazepine | 70 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 16 |
| Botox | Onabotulinumtoxina | 48 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 12 |
| Alprazolam | Alprazolam | 47 | 13 |
| Nurtec Odt | Rimegepant Sulfate | 45 | 15 |
| Nuplazid | Pimavanserin Tartrate | 44 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Pregabalin | Pregabalin | 36 | 13 |
| Aimovig Autoinjector | Erenumab-Aooe | 34 | suppressed |
| Baclofen | Baclofen | 33 | 12 |
| Carbamazepine | Carbamazepine | 33 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 32 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Rytary | Carbidopa/Levodopa | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 24 | suppressed |
| Amantadine | Amantadine Hcl | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Lisinopril | Lisinopril | 20 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 19 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 18 | suppressed |
| Zonisamide | Zonisamide | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 16 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 16 | suppressed |
| Ongentys | Opicapone | 16 | suppressed |
| Briviact | Brivaracetam | 15 | suppressed |
| Dalfampridine Er | Dalfampridine | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 15 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Nourianz | Istradefylline | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Gocovri | Amantadine Hcl | 12 | suppressed |
| Kesimpta Pen | Ofatumumab | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Levetiracetam Er | Levetiracetam | 11 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $80,846.86 · 459 records | ACADIA Pharmaceuticals Inc | ACTHAR, AMYVID, AUSTEDO XR, BOTOX, BRIUMVI, Bafiertam, Briviact, CREXONT, FIRDAPSE, Fintepla, Gamunex-C, HORIZANT, Hizentra, INGREZZA, KESIMPTA, KISUNLA, Leqembi, NUPLAZID, NURTEC ODT, Nayzilam, ONPATTRO, Ocrevus, Ocrevus Zunovo, PANZYGA, PONVORY, PURIFIED CORTROPHIN GEL, Privigen, QULIPTA, QUTENZA, REXULTI, Rystiggo, Symbravo, TRUDHESA, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, XCOPRI, ZAVZPRET, ZEPOSIA, ZTLido, Zilbrysq | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error